Telix at ANZSNM Annual Scientific Meeting
13 May 2021 – Clinical Spotlight | Telix to Sponsor Pre-Conference Symposium at 51st Australian and New Zealand Society of Nuclear Medicine Annual Scientific Meeting
Telix is pleased to announce our participation in the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting to be held 21 – 23 May 2021, live and local.
We are proud to sponsor the Pre-Conference Symposium, entitled: “Therapeutic Nuclear Medicine – A New Era in Oncology”, which takes place next Friday, 21 May at 10.15 am (AEST).
An expert line up of speakers will cover topics including Telix’s Phase III “ProstACT” trial announced this week for advanced prostate cancer therapy, plus Telix’s Phase I/II “IPAX” therapeutic study for relapsed glioblastoma, the most common and aggressive form of primary brain cancer.
The symposium will be chaired by Dr. Danielle Meyrick, Telix’s Chief Medical Officer for APAC, with an opportunity for Q&A following speaker presentations.
- Session: Therapeutic Nuclear Medicine – A New Era in Oncology
- Format: Hybrid event (registration required, see link below)
- Date/time: 21 May 2021, 10.15 am – 12.15 pm (AEST).
To register for the ANZSNM Annual Scientific Meeting please click here.
To view the conference program please click here.
To return to the Telix homepage please click here.